EPR22-112: Risk of Prostate Cancer for Metformin Versus Sulphonylurea Monotherapy in Type 2 Diabetes Mellitus: A Propensity Score-Matched Retrospective Cohort Study

Authors:
Yan Hiu Athena Lee Cardiovascular Analytics Group, Hong Kong, China-UK Collaboration

Search for other papers by Yan Hiu Athena Lee in
Current site
Google Scholar
PubMed
Close
 N/A
,
Jiandong Zhou City University of Hong Kong, Hong Kong, China

Search for other papers by Jiandong Zhou in
Current site
Google Scholar
PubMed
Close
 PhD
,
Jeremy Man Ho Hui Cardiovascular Analytics Group, Hong Kong, China-UK Collaboration

Search for other papers by Jeremy Man Ho Hui in
Current site
Google Scholar
PubMed
Close
 N/A
,
Xuejin Liu Kaili University, Kaili City, Guizhou, China

Search for other papers by Xuejin Liu in
Current site
Google Scholar
PubMed
Close
 MSc
,
Teddy Tai Loy Lee Cardiovascular Analytics Group, Hong Kong, China-UK Collaboration
Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

Search for other papers by Teddy Tai Loy Lee in
Current site
Google Scholar
PubMed
Close
 N/A
,
Kyle Hui Cardiovascular Analytics Group, Hong Kong, China-UK Collaboration

Search for other papers by Kyle Hui in
Current site
Google Scholar
PubMed
Close
 N/A
,
Abraham Ka Chung Wai Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

Search for other papers by Abraham Ka Chung Wai in
Current site
Google Scholar
PubMed
Close
 MBChB, FRCEM, FRCP
,
Wing Tak Wong Chinese University of Hong Kong, Hong Kong, China

Search for other papers by Wing Tak Wong in
Current site
Google Scholar
PubMed
Close
 PhD
,
Tong Liu Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China

Search for other papers by Tong Liu in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Kenrich Ng University College London Hospitals NHS Foundation Trust, London, UK

Search for other papers by Kenrich Ng in
Current site
Google Scholar
PubMed
Close
 MA, MBBChir, MRCP
,
Sharen Lee Cardiovascular Analytics Group, Hong Kong, China-UK Collaboration

Search for other papers by Sharen Lee in
Current site
Google Scholar
PubMed
Close
 N/A
,
Edward Christopher Dee Harvard Medical School, Boston, MA

Search for other papers by Edward Christopher Dee in
Current site
Google Scholar
PubMed
Close
 MD
,
Jeffrey Shi Kai Chan Cardiovascular Analytics Group, Hong Kong, China-UK Collaboration

Search for other papers by Jeffrey Shi Kai Chan in
Current site
Google Scholar
PubMed
Close
 MBChB
,
Qingpeng Zhang City University of Hong Kong, Hong Kong, China

Search for other papers by Qingpeng Zhang in
Current site
Google Scholar
PubMed
Close
 PhD
, and
Gary Tse Cardiovascular Analytics Group, Hong Kong, China-UK Collaboration
Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China
Kent and Medway Medical School, Canterbury, Kent, CT2 7NT, UK

Search for other papers by Gary Tse in
Current site
Google Scholar
PubMed
Close
 MD, PhD, FRCP, FFPH

Background: Metformin may have anticancer effects, but its role on prostate cancer remains inconclusive. We thus compared the differences in the risk of prostate cancer between metformin and sulphonylurea users with type 2 diabetes mellitus (T2DM). Methods: This retrospective cohort study included male patients with T2DM attending public hospitals/clinics in Hong Kong between 1 Jan 2000 and 31 Dec 2009 as recorded by a local territory-wide clinical database that captures key demographic, clinical and medication records of all patients attending public healthcare services in Hong Kong. All patients were followed up till 31 Dec 2019. The outcome of interest was prostate cancer. We excluded patients with baseline age <18 years old, prior diagnoses of cancer, prescriptions of both metformin and sulphonylurea or neither. 1:1 propensity score matching was performed based on demographics, Charlson comorbidity index, past comorbidities, non-metformin/sulphonylurea medications, anti-diabetic and cardiovascular medications, and HbA1c. Results: Screening of the clinical database using the inclusion and exclusion criteria identified 67471 male patients who were eligible for matching. Propensity score matching matched 26109 metformin users in a 1:1 ratio to sulfonylurea users, producing a final cohort of 52218 male patients (mean age 68.6±12.1 years, mean follow-up 9.3±3.5 years). Prostate cancer occurred in 382 metformin users (crude rate: 1.46%) and 1154 sulphonylurea users (crude rate: 4.41%). Cox regression analysis demonstrated that metformin users had lower risks of prostate cancer than sulfonylurea users (hazard ratio 0.32, 95% confidence interval [0.29, 0.36], p<0.0001). Conclusion: Metformin use, compared to sulphonylurea use, was associated with lower risks of prostate cancer in patients with T2DM. This study highlights the importance of pharmaceutical choice for patients with T2DM at high risks of prostate cancer.

Corresponding Author: Gary Tse, MD, PhD, FRCP, FFPH
  • Collapse
  • Expand